MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
4.530
-0.230
-4.83%
Opening 11:35 02/08 EST
OPEN
4.760
PREV CLOSE
4.760
HIGH
4.760
LOW
4.510
VOLUME
123.56K
TURNOVER
399.93K
52 WEEK HIGH
9.60
52 WEEK LOW
3.151
MARKET CAP
863.99M
P/E (TTM)
-2.8203
1D
5D
1M
3M
1Y
5Y
Sana Biotechnology: Time And Cash Burn Are The Enemies
Seeking Alpha · 18m ago
Sana Biotechnology A Buy On Low Price And First IND
Seeking Alpha · 2h ago
Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update
Seeking Alpha · 01/30 05:27
BRIEF-Sana Biotechnology Announces FDA Nod For Human Clinical Trials For Car T Therapy For B-Cell Malignancies
Reuters · 01/26 22:29
Sana Biotechnology gains FDA IND clearance for CAR T therapy for B-cell malignancies
Seeking Alpha · 01/26 21:43
Sana Biotechnology Says FDA Clears Investigational New Drug Application for SC291 Therapy Study
Sana Biotechnology Says FDA Clears Investigational New Drug Application for SC291 Therapy Study
MT Newswires · 01/26 17:46
Morgan Stanley Remains a Buy on Sana Biotechnology (SANA)
TipRanks · 01/24 16:26
--Morgan Stanley Adjusts Price Target on Sana Biotechnology to $13 From $15, Maintains Overweight Rating
--Morgan Stanley Adjusts Price Target on Sana Biotechnology to $13 From $15, Maintains Overweight Rating
MT Newswires · 01/24 10:45
More
About SANA
Sana Biotechnology, Inc. is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The Company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

Webull offers kinds of Sana Biotechnology Inc stock information, including NASDAQ:SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.